This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

High Degree of Tolerability for Monotherapy With High Doses of Quetiapine: A Case Report

Julio Bobes, Maria P. Garcia-Portilla, Pilar A. Saiz, Maria-Teresa Bascaran, Manuel Bousoão, and Celso Arango

Published: November 1, 2002

Article Abstract

Letter to the Editor

Sir: Quetiapine is a relatively new third-generation antipsychotic with a labeled dose range of 400 to 800 mg/day. Quetiapine has demonstrated efficacy in the management of patients with a history of partial response to conventional antipsychotics. We report the case of a schizophrenic woman who achieved full clinical remission without significant side effects with a high dose of quetiapine (1600 mg/day). To our knowledge, evidence from daily clinical practice or controlled clinical trials has never been published on high doses of this new antipsychotic.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 63

Quick Links: